T&R Biofab secures patent for ventricular cardiomyocyte purification technology, accelerating heart regeneration therapy development

T&R Biofab, a South Korean regenerative medicine company, announced on June 29, 2026, that it has secured a domestic patent for a method to purify and manufacture ventricular cardiomyocytes derived from induced pluripotent stem cells (iPSCs). The patented technology uses surface markers including CD81, IL1RL1, and CD59 to selectively isolate high-purity ventricular cardiomyocytes, addressing a longstanding challenge in cardiac cell therapy where differentiation processes produce a mixed population of atrial, ventricular, and nodal cells. The research was conducted under the Multi-Ministry Regenerative Medicine Technology Development Project, a Korean government-funded initiative aimed at commercializing iPSC-derived ventricular cardiomyocyte production. The company plans to integrate this cell purification capability with its existing 3D bioprinting and extracellular matrix (ECM) biomaterial platforms to develop cardiac spheroids and cardiac patches for heart tissue regeneration.

This patent represents a meaningful step in bridging the gap between bioprinting tool capability and therapeutic product viability. While the broader bioprinting field has produced impressive tissue constructs in academic settings, the path to clinical cell therapy requires solving manufacturing challenges around cell purity, batch consistency, and scalable production - precisely the bottlenecks this technology targets. T&R Biofab's approach of combining iPSC differentiation control with 3D bioprinting and ECM scaffolds positions it within a small cohort of companies attempting to move from tissue modeling into actual therapeutic products. The company's existing portfolio includes 3D-printed cranial implants and orthopedic regenerative devices, suggesting a deliberate strategy of building clinical manufacturing experience across multiple tissue types before tackling the higher-complexity cardiac market. The patent also strengthens T&R Biofab's intellectual property position in the competitive Korean regenerative medicine landscape, where government funding increasingly favors projects with clear commercialization pathways.

From a practical standpoint, this patent is a process-enabling milestone rather than a therapeutic breakthrough. The company still needs to demonstrate that its purified ventricular cardiomyocytes can engraft, survive, and functionally integrate in preclinical heart failure models, then navigate the regulatory pathway for cell-based combination products that incorporate both bioprinted scaffolds and living cells. For the bioprinting industry, the real signal is that T&R Biofab is treating its printing platform as a manufacturing tool for regulated therapeutics, not just a research instrument - a distinction that matters as the field seeks to demonstrate clinical and commercial credibility beyond academic publications.